+44 (0) 1793 575 050
customerservice@regenmedical.co.uk

Part of the Joint Operations family

GET IN TOUCH TO FIND OUT MORE

About MiMedx

MiMedx is the leading global supplier of amniotic tissue, and the Company has supplied over 1,000,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare.

MiMedx is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare.

MiMedx platform technologies include EpiFix® human amnion/chorion membrane allografts which are processed utilizing our proprietary PURION® process to produce an easy to use and effective implant that can be stored at ambient conditions. EpiFix provides a scaffold for cellular ingrowth, modulates inflammation, and reduces scar tissue formation for enhanced healing. To date, over 40 clinical and scientific papers have been published in peer-reviewed journals on MiMedx allografts. MiMedx products are immunologically privileged, meaning a minimized risk of a patient’s reaction or rejection of a graft.

MiMedx has demonstrated in several peer-reviewed publications that PURION Processed dHACM recruits stem cells, promotes migration, and modulates stem cell activity in vitro and in vivo compared to appropriate controls.

MiMedx products contain human placental tissue-derived collagen, growth factors, cytokines and chemokines that are known to be therapeutic regulators of inflammation, angiogenesis, and wound healing.

About MiMedx

MiMedx is the leading global supplier of amniotic tissue, and the Company has supplied over 1,000,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare.

MiMedx is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare.

MiMedx platform technologies include EpiFix® human amnion/chorion membrane allografts which are processed utilizing our proprietary PURION® process to produce an easy to use and effective implant that can be stored at ambient conditions. EpiFix provides a scaffold for cellular ingrowth, modulates inflammation, and reduces scar tissue formation for enhanced healing. To date, over 40 clinical and scientific papers have been published in peer-reviewed journals on MiMedx allografts. MiMedx products are immunologically privileged, meaning a minimized risk of a patient’s reaction or rejection of a graft.

MiMedx has demonstrated in several peer-reviewed publications that PURION Processed dHACM recruits stem cells, promotes migration, and modulates stem cell activity in vitro and in vivo compared to appropriate controls.

MiMedx products contain human placental tissue-derived collagen, growth factors, cytokines and chemokines that are known to be therapeutic regulators of inflammation, angiogenesis, and wound healing.

GET IN TOUCH TO FIND OUT MORE